The holy grail: pan-cancer-targeting T cells

Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.

Frontiers It's Getting Complicated—A Fresh Look at p53-MDM2-ARF

IJMS, Free Full-Text

Role of nanotechnology and gene delivery systems in TRAIL based

Weekly Digests for February 2020

Our strategy - MYCimmune

Cancers, Free Full-Text

IJMS, Free Full-Text

Frontiers Targeting KRAS mutations in pancreatic cancer

Dr Ying-Xian Pan - The Holy Grail of Safer Opioids: Targeting Mu

A Road Map to Personalizing Targeted Cancer Therapies Using

Frontiers Adoptive NK Cell Therapy - a Beacon of Hope in

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1

Frontiers CAR T Cells for Acute Myeloid Leukemia: State of the